Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 6/20 | 0.52 |
| ▸ | EGFR | P00533 | 9/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24674518 | 0.85 | CCNE2 (0.40) | MAP4K4EGFRCCNE2CCNE1CDK2 | |
| SCHEMBL34463746 | 0.85 | CCNE2 (0.40) | MAP4K4EGFRCCNE2CCNE1CDK2 | |
| SCHEMBL22726095 | 0.83 | MAP4K4 (0.42) | MAP4K4CCNE2CCNE1CDK2 | |
| SCHEMBL24674533 | 0.82 | CCNE2 (0.40) | MAP4K4EGFRCCNE2CCNE1CDK2 | |
| SCHEMBL24673910 | 0.81 | EGFR (0.53) | EGFRCCNE2CCNE1CDK2DYRK1A | |
| SCHEMBL29427613 | 0.81 | EGFR (0.53) | EGFRCCNE2CCNE1CDK2DYRK1A | |
| SCHEMBL28713734 | 0.81 | EGFR (0.53) | EGFRCCNE2CCNE1CDK2DYRK1A | |
| SCHEMBL22745128 | 0.81 | EGFR (0.66) | EGFRDYRK1APIK3CA | |
| SCHEMBL28726498 | 0.81 | EGFR (0.66) | EGFRDYRK1APIK3CA | |
| SCHEMBL29481331 | 0.81 | EGFR (0.66) | EGFRDYRK1APIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976609-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-04-06 | — | — | EP | claimed |
| US-12606562-B2 | Pyridopyrimidines derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-04-21 | — | — | US | disclosed |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-06 | — | — | US | disclosed |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-06 | — | — | US | disclosed |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-06 | — | — | US | disclosed |
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2022-07-28 | — | — | US | disclosed |
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | MAP4K4 2070/4885EGFR 1611/4885CCNE2 3793/4885 |
| US-12606562-B2 | Pyridopyrimidines derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX2 | MAP4K4 3995/4885EGFR 1092/4885CCNE2 4076/4885 |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | MAP4K4 2070/4885EGFR 1611/4885CCNE2 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.